((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
Oct. 16 – **Shares of Capricor Therapeutics CAPR.O fell 8.6% to $18.75 in extended trading, as the company seeks to raise capital** San Diego-based biotechnology company announces an offering of shares on; the amount of the transaction was not disclosed
**Piper Sandler and Oppenheimer are lead bookrunners
**The Company intends to use the net proceeds from the offering for continued development and manufacturing of the product candidates, working capital and general corporate purposes
**CAPR shares closed Wednesday down 5% at $20.51
**The company has approximately 32.54 million shares outstanding for a market capitalization of approximately $668 million and a float of approximately 24.93 million shares, according to LSEG** Shares closed at $5.97 on September 23, a day before the company announced plans to file a Biologics License Application (BLA) with the U.S. FDA to seek full approval of its treatment for Duchenne muscular dystrophy ((DMD) cardiomyopathy)
